Status:
COMPLETED
Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
Lead Sponsor:
University Medical Center Groningen
Conditions:
Epithelial Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
Molecularly targeted agents which inhibit the mammalian target of rapamycin (mTOR) pathway and/or circumvent p53 in the induction of apoptosis are exciting potential targets in ovarian cancer. Metform...
Detailed Description
A phase Ib, single-centre, dose-escalation trial with a traditional escalation rule with fixed dose levels ("3 + 3" rule). The recommended phase II dose will be defined as the maximum predefined dose ...
Eligibility Criteria
Inclusion
- Patients with advanced stage (FIGO III-IV), histologically confirmed and documented epithelial ovarian carcinoma
- Patients eligible for neo-adjuvant carboplatin/paclitaxel chemotherapy prior to surgical debulking OR patients with relapsed or progressive ovarian cancer after initial treatment eligible for palliative carboplatin/paclitaxel chemotherapy
- Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0-2
- Age ≥ 18 years
- Laboratory Requirements - within 7 days prior to enrolment:
- absolute neutrophil count (ANC) ≥1.5 x 109/L
- platelets \> 100 x 109/L
- hemoglobin \>9g/dl. Patients may be transfused or use erythropoietin to maintain hemoglobin values ≥ 9 g/dl.
- hepatic function: bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST)/ALT≤2.5×ULN
- estimated creatinine clearance ≥ 60ml/min
- Before patient registration/randomization, written informed consent for the trial must be given according to International Conference on Harmonisation (ICH)/ good clinical practice (GCP), and national/local regulations.
Exclusion
- Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study.
- Metformin within 4 weeks prior to enrolment.
- Symptomatic central nervous system (CNS) metastasis
- Pre-existing peripheral neuropathy ≥ Common toxicity criteria (CTC) grade 2.
- Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start.
- Women of childbearing potential (defined as \<2 years after last menstruation and not surgically sterile) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the study and for 6 months after the last study medication.
- Known hypersensitivity to any of the study drugs or excipients.
- Serious active infection requiring i.v. antibiotics at enrolment.
- Unstable medical conditions.
- Evidence of any other medical conditions, physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications.
Key Trial Info
Start Date :
October 5 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT02312661
Start Date
October 5 2015
End Date
November 1 2017
Last Update
May 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Mecdical Center Groningen
Groningen, Netherlands, 9713 GZ